Keywords: genentech, earnings, leap, avastin, weakness, causes, shares
Genentech's earnings leap 79% but Avastin weakness causes shares to drop 3%
Article | 17 July 2006
The USA's second-largest biotechnology firm, Genentech, posted a massive leap in second-quarter 2006 net income but, because of some weakness in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
